Trends in drug treatment of benign prostatic hyperplasia in Japan based on the National Database Open Data
Although BPH medication prescriptions are increasing, driven by Japan's aging population and clinical guidelines, market dynamics are shifting owing to generic and government price adjustments. This analysis underscores the changing BPH treatment landscape in Japan, highlighting the importance of continuous evaluation of treatment efficacy and cost-effectiveness in evolving healthcare policies and demographics.
Authors
- Motofumi Suzuki (ORCID: https://orcid.org/0000-0003-2552-1964)
- Yoshinori Nishino (ORCID: https://orcid.org/0000-0002-7215-8013)
- Satoru Takahashi (ORCID: https://orcid.org/0000-0002-0819-9478)
- Masaki Nakamura (ORCID: https://orcid.org/0000-0002-7473-3325)
- Haruki Kume (ORCID: https://orcid.org/0000-0001-9841-0857)
- Ken-ichi Sasaki (ORCID: https://orcid.org/0000-0002-0658-4911)
Institutions
- Nihon University (JP)
- Kikkoman (Japan) (JP)
- NTT Medical Center (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- International Journal of Urology
- Published
- 2024-09-02
- DOI
- https://doi.org/10.1111/iju.15570
- Citations
- 2
- Primary Topic
- Urinary Bladder and Prostate Research
- Type
- article
- Field-Weighted Citation Impact
- 1.07